These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19568963)

  • 1. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate.
    Schilcher J; Aspenberg P
    Acta Orthop; 2009 Aug; 80(4):413-5. PubMed ID: 19568963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.
    Isaacs JD; Shidiak L; Harris IA; Szomor ZL
    Clin Orthop Relat Res; 2010 Dec; 468(12):3384-92. PubMed ID: 20809164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of incomplete atypical femoral fractures in patients after a prolonged and variable course of bisphosphonate therapy-a long-term radiological follow-up.
    Png MA; Mohan PC; Koh JSB; Howe CY; Howe TS
    Osteoporos Int; 2019 Dec; 30(12):2417-2428. PubMed ID: 31435684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.
    Lenart BA; Neviaser AS; Lyman S; Chang CC; Edobor-Osula F; Steele B; van der Meulen MC; Lorich DG; Lane JM
    Osteoporos Int; 2009 Aug; 20(8):1353-62. PubMed ID: 19066707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy?
    Ha YC; Cho MR; Park KH; Kim SY; Koo KH
    Clin Orthop Relat Res; 2010 Dec; 468(12):3393-8. PubMed ID: 20865463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates.
    Sato H; Kondo N; Wada Y; Nakatsue T; Iguchi S; Fujisawa J; Kazama JJ; Kuroda T; Nakano M; Endo N; Narita I
    Osteoporos Int; 2016 Mar; 27(3):1217-1225. PubMed ID: 26519417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Femoral insufficiency fractures with bisphosphonate therapy. Cases study.
    Boszczyk A; Kowalski D; Zakrzewski P; Pomianowski S
    Ortop Traumatol Rehabil; 2011; 13(4):403-8. PubMed ID: 21857071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use.
    Meier RP; Perneger TV; Stern R; Rizzoli R; Peter RE
    Arch Intern Med; 2012 Jun; 172(12):930-6. PubMed ID: 22732749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures.
    Banffy MB; Vrahas MS; Ready JE; Abraham JA
    Clin Orthop Relat Res; 2011 Jul; 469(7):2028-34. PubMed ID: 21350886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of atypical femoral fracture during and after bisphosphonate use.
    Schilcher J; Koeppen V; Aspenberg P; Michaëlsson K
    Acta Orthop; 2015 Feb; 86(1):100-7. PubMed ID: 25582459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals.
    Thompson RN; Phillips JR; McCauley SH; Elliott JR; Moran CG
    J Bone Joint Surg Br; 2012 Mar; 94(3):385-90. PubMed ID: 22371548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dichotomous location of 160 atypical femoral fractures.
    Koeppen VA; Schilcher J; Aspenberg P
    Acta Orthop; 2013 Dec; 84(6):561-4. PubMed ID: 24286566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan.
    Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
    Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate use and atypical fractures of the femoral shaft.
    Schilcher J; Michaëlsson K; Aspenberg P
    N Engl J Med; 2011 May; 364(18):1728-37. PubMed ID: 21542743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilateral low-energy sequential femoral shaft fractures in patients on long-term bisphosphonate therapy.
    Çakmak S; Mahiroğulları M; Keklikçi K; Sarı E; Erdik B; Rodop O
    Acta Orthop Traumatol Turc; 2013; 47(3):162-72. PubMed ID: 23748615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-associated fractures of the femur: pathophysiology and treatment.
    Einhorn TA; Bogdan Y; Tornetta P
    J Orthop Trauma; 2014 Jul; 28(7):433-8. PubMed ID: 24121986
    [No Abstract]   [Full Text] [Related]  

  • 17. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates.
    Nieves JW; Cosman F
    Curr Osteoporos Rep; 2010 Mar; 8(1):34-9. PubMed ID: 20425089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of incomplete atypical femoral fractures in asymptomatic patients on long-term bisphosphonate therapy.
    La Rocca Vieira R; Rosenberg ZS; Allison MB; Im SA; Babb J; Peck V
    AJR Am J Roentgenol; 2012 May; 198(5):1144-51. PubMed ID: 22528906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Atypical femoral fracture associated with the use of bisphosphonates, an adverse drug reaction not to be missed].
    Ing Lorenzinit K; Meier R; Suva D; Dayer P; Desmeules J; Peter R
    Rev Med Suisse; 2012 Jun; 8(344):1238-42. PubMed ID: 22730621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term radiographic follow-up of bisphosphonate-associated atypical femur fractures.
    Favinger JL; Hippe D; Ha AS
    Skeletal Radiol; 2016 May; 45(5):627-33. PubMed ID: 26880003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.